R-Pharm US has a robust global pipeline:
IXEMPRA® (ixabepilone)
- IXEMPRA® (ixabepilone) is a microtubule inhibitor that is indicated for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline and a taxane. It can be used in combination with capecitabine or as a monotherapy. To see full US Prescribing Information for IXEMPRA, including Boxed Warning regarding hepatic impairment, visit www.Ixempra.com.
- IXEMPRA® (ixabepilone) is being investigated in advanced ovarian cancer including platinum resistant and platinum refractory patients.